Actinium announced ATNM-400, a novel, non-PSMA targeting, first in class radiotherapy for prostate cancer utilizing the Actinium-225 radioisotope. Initial preclinical data from ATNM-400 will be ...

(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM) Tuesday has launched a clinical program evaluating Actimab-A in combination with the PD-1 inhibitors pembrolizumab - KEYTRUDA and nivolumab OPDIVO.

I n a challenging year for Actinium Pharmaceuticals (NYSE:ATNM), the company's stock has touched a 52-week low, trading at $1.1, marking an 80% decline from its 52-week high of $10.24. According ...

Actinium-225 offers a different approach by using alpha particles instead of beta particles. Alpha particles are highly energetic and travel only a short distance, which allows them to effectively ...

Actinium's Chairman and CEO, said, "The current era of radiotherapy is built on the clinical and commercial success of Pluvicto in prostate cancer. The field is now looking to address patients ...

Sandesh Seth, Chairman and CEO at Actium Pharmaceuticals, Inc. commented: "We believe that targeted radiation therapy with Actinium-225 is one of the most promising approaches for treating ...

Actinium Pharmaceuticals has a 52-week low of $1.03 and a 52-week high of $10.24. A number of institutional investors have recently bought and sold shares of ATNM. Geode Capital Management LLC ...

Actinium Pharmaceuticals (ATNM) has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center to expand Actimab-A’s mutation agnostic mechanism of action. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a developer of targeted radiotherapies, announced the introduction of ATNM-400, a new radiotherapy for prostate cancer, and ...

Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting ...